BioCentury
ARTICLE | Clinical News

QLT091001: Phase Ib started

December 21, 2009 8:00 AM UTC

QLT began an open-label, Canadian Phase Ib trial to evaluate oral QLT091001 given once daily for 7 days in 8 pediatric patients with inherited deficiency of retinal pigment epithelium protein 65 (RPE6...